Triple

T17354567
Position Surface form Disambiguated ID Type / Status
Subject Rare Diseases Act of 2002 E421900 entity
Predicate relatedTo P37 FINISHED
Object Orphan Drug Act — NE ONNED1

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Orphan Drug Act | Statement: [Rare Diseases Act of 2002, relatedTo, Orphan Drug Act]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Orphan Drug Act
Context triple: [Rare Diseases Act of 2002, relatedTo, Orphan Drug Act]
  • A. Orphan Drug Act of 1983 chosen
    The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
  • B. Drug Price Competition and Patent Term Restoration Act of 1984
    The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
  • C. Food and Drug Administration Amendments Act of 2007
    The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
  • D. Compassionate Use Act of 1996
    The Compassionate Use Act of 1996 is a California voter-approved law that legalized medical marijuana use for patients with a physician’s recommendation, making California the first U.S. state to permit medical cannabis.
  • E. Rare Diseases Act of 2002
    The Rare Diseases Act of 2002 is a U.S. federal law that expanded national efforts to identify, study, and develop treatments for rare diseases by strengthening research infrastructure and coordination.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d889d520008190a26917a95bf1c2ea completed April 10, 2026, 5:25 a.m.
NER Named-entity recognition batch_69e43a2f26548190a8822b2470ec3c72 completed April 19, 2026, 2:13 a.m.
NED1 Entity disambiguation (via context triple) batch_6a01955a50dc819090c1a0ec111d9fc0 in_progress May 11, 2026, 8:37 a.m.
Created at: April 10, 2026, 5:44 a.m.